LEO Pharma Acquires Timber Pharmaceuticals (TMB-001) in Up to $36 Million Deal
August 21, 2023
LEO Pharma signed an agreement to acquire U.S.-listed Timber Pharmaceuticals in a deal valued at up to $36 million. The transaction will add Timber’s late-stage dermatology asset, TMB-001 (topical reformulation of isotretinoin for congenital ichthyosis), to LEO Pharma’s pipeline; closing is expected in Q4 2023, subject to shareholder approval and other conditions.
- Buyers
- LEO Pharma
- Targets
- Timber Pharmaceuticals
- Industry
- Healthcare Services
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
LEO Pharma to Acquire Worldwide Rights to Dersimelagon From Tanabe Pharma
August 18, 2026
Pharmaceuticals
LEO Pharma entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma. The oral, once-daily MC1R agonist is in development for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), with LEO Pharma expecting pre-launch investments in 2026 and a potential launch in 2027. The deal includes up to USD 435 million in upfront and near-term milestone payments plus potential downstream milestones and tiered royalties.
-
LEO Pharma to Acquire Replay Gene Therapy Platform
April 30, 2026
Healthcare Services
LEO Pharma has entered into a definitive agreement to acquire Replay, a gene therapy company developing treatments for rare genetic dermatological conditions. The acquisition adds Replay’s high-payload herpes simplex virus (HSV) delivery vector platform to LEO Pharma’s dermatology pipeline, with the lead program targeting dystrophic epidermolysis bullosa (DEB) currently in preclinical studies.
-
Otsuka Pharmaceutical Acquires Transcend Therapeutics
March 27, 2026
Biotechnology
Otsuka Pharmaceutical Co., Ltd. entered into an agreement to acquire clinical-stage biotech company Transcend Therapeutics, which is developing rapid-acting treatments for neuropsychiatric disorders, including its lead program TSND-201 (methylone) for PTSD. Otsuka would pay $700 million upfront at closing and up to $525 million in contingent milestone payments, with completion expected in Q2 2026; the acquisition has since been completed.
-
Star Equity Holdings Acquires Timber Technologies
May 17, 2024
Building Products
Star Equity Holdings, Inc. completed the acquisition of Timber Technologies, LLC (Timber Tech), a Colfax, Wisconsin-based glue-laminated timber (glulam) manufacturer, effective May 17, 2024. The cash-free, debt-free purchase price was $23 million (including upfront cash, deferred cash and an earn-out), with associated real estate to be acquired separately for $3 million; Timber Tech reported 2023 revenue of $18.8 million and Adjusted EBITDA of $5.5 million.
-
Takeda Acquires Nimbus Therapeutics' TYK2 Program Subsidiary (Nimbus Lakshmi)
February 8, 2023
Pharmaceuticals
Takeda Pharmaceutical Company Limited has completed the acquisition of all shares of Nimbus Lakshmi, Inc. (the TYK2 program subsidiary of Nimbus Therapeutics) for approximately $4.0 billion upfront, with up to $2.0 billion in potential milestone payments. The deal adds TAK-279 (NDI-034858), a selective oral TYK2 inhibitor moving into late‑stage development, strengthening Takeda's late‑stage pipeline in immune‑mediated diseases including psoriasis and other immunological indications.
-
BioPharmX Corp to Merge with Timber Pharmaceuticals
January 28, 2020
Pharmaceuticals
BioPharmX Corporation (NYSE American: BPMX) entered into a definitive merger agreement with Timber Pharmaceuticals LLC whereby a BioPharmX subsidiary will merge into Timber, leaving Timber as a wholly‑owned subsidiary of BioPharmX. The transaction will bring at least $20 million of financing to the combined company, after which BioPharmX will change its name to Timber Pharmaceuticals and Timber’s management will become the combined company's leadership.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.